Skip to main content

A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel

Publication ,  Journal Article
Ross, RW; Beer, TM; Jacobus, S; Bubley, GT; Taplin, M-E; Ryan, C; Huang, J; Oh, WK
Published in: Cancer
2008

Duke Scholars

Published In

Cancer

Publication Date

2008

Volume

112

Start / End Page

521 / 526

Related Subject Headings

  • Oncology & Carcinogenesis
  • 4206 Public health
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ross, R. W., Beer, T. M., Jacobus, S., Bubley, G. T., Taplin, M.-E., Ryan, C., … Oh, W. K. (2008). A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer, 112, 521–526.
Ross, R. W., T. M. Beer, S. Jacobus, G. T. Bubley, M. -. E. Taplin, C. Ryan, J. Huang, and W. K. Oh. “A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.” Cancer 112 (2008): 521–26.
Ross RW, Beer TM, Jacobus S, Bubley GT, Taplin M-E, Ryan C, et al. A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–6.
Ross RW, Beer TM, Jacobus S, Bubley GT, Taplin M-E, Ryan C, Huang J, Oh WK. A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–526.

Published In

Cancer

Publication Date

2008

Volume

112

Start / End Page

521 / 526

Related Subject Headings

  • Oncology & Carcinogenesis
  • 4206 Public health
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis